Result of phase II clinical trial of herceptin in advanced Chinese breast cancer patients / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 581-583, 2003.
Artículo
en Chino
| WPRIM
| ID: wpr-271075
ABSTRACT
<p><b>OBJECTIVE</b>To observe the clinical efficacy and adverse effects of herceptin for advanced Chinese breast cancer patients.</p><p><b>METHODS</b>Thirty-one pathologically proved advanced breast cancer women were treated by herceptin. In the first week, a loading dose 4 mg/kg was administered by intravenous infusion and from the second week, a routine dose of 2 mg/kg was given every week for at least 3 months.</p><p><b>RESULTS</b>There were 2 CR, 6 PR, 7 SD, and 16 PD among 31 patients after treatment by herceptin, the response rate being 25.8%. In factors influencing the prognosis, age and general condition were factors favoring the results, and pathological type, site of metastasis, grade of her-2 over expression and prior treatment were irrelevant to the results. The adverse effects were mild but different from those of the common anticancer drugs.</p><p><b>CONCLUSION</b>Herceptin is effective and well tolerated by the Chinese breast cancer patients.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias de la Mama
/
Usos Terapéuticos
/
Quimioterapia
/
Anticuerpos Monoclonales Humanizados
/
Trastuzumab
/
Anticuerpos Monoclonales
Tipo de estudio:
Estudio pronóstico
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2003
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS